Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 730 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Teacher’s Mental Health Check-In Board Goes Viral For The ‘Beautiful’ Standard... April 11, 2019 Diagnosed 3 Weeks Before Her Wedding, She Finally Gets To Ring... October 11, 2019 New on NCI’s Websites for September 2020 September 2, 2020 Second-line Sintilimab Improves Survival Over Docetaxel in Squamous Non-Small Cell Lung... December 11, 2020 Load more HOT NEWS Patients with Early Stage NSCLC Have a Higher TMB in Comparison... Could a Vaccine Prevent Colorectal Cancer in People with Lynch Syndrome? FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple... ESMO Immuno-Oncology Virtual Congress 2020
